[HTML][HTML] Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming

R Mattioli, A Ilari, B Colotti, L Mosca, F Fazi… - Molecular Aspects of …, 2023 - Elsevier
Anthracyclines have been important and effective treatments against a number of cancers
since their discovery. However, their use in therapy has been complicated by severe side …

Antitumour anthracyclines: progress and perspectives

MB Martins‐Teixeira, I Carvalho - ChemMedChem, 2020 - Wiley Online Library
Anthracyclines are ranked among the most effective chemotherapeutics against cancer.
They are glycoside drugs comprising the amino sugar daunosamine linked to a hydroxy …

Systemic therapy for small-cell lung cancer: ASCO-Ontario health (cancer care Ontario) guideline

H Khurshid, N Ismaila, J Bian, R Dabney… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on the
management of patients with small-cell lung cancer. METHODS An Expert Panel of medical …

Interactions of the antioxidant enzymes NAD (P) H: Quinone oxidoreductase 1 (NQO1) and NRH: Quinone oxidoreductase 2 (NQO2) with pharmacological agents …

MH Rashid, D Babu, AG Siraki - Chemico-Biological Interactions, 2021 - Elsevier
Abstract NAD (P) H: Quinone Oxidoreductase 1 (NQO1) is an antioxidant enzyme that
catalyzes the two-electron reduction of several different classes of quinone-like compounds …

[HTML][HTML] Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer

JY Lee, RR Bhandare, SHS Boddu, AB Shaik… - Biomedicine & …, 2024 - Elsevier
Tumour suppressor genes play a cardinal role in the development of a large array of human
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer

H Imai, Y Nagai, H Minemura, T Tsuda… - Investigational New …, 2022 - Springer
This study examined the activity and safety of amrubicin monotherapy among relapsed small-
cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus …

Breaking the bottleneck in anticancer drug development: Efficient Utilization of Synthetic Biology

H Wang, Y He, M Jian, X Fu, Y Cheng, Y He, J Fang… - Molecules, 2022 - mdpi.com
Natural products have multifarious bioactivities against bacteria, fungi, viruses, cancers and
other diseases due to their diverse structures. Nearly 65% of anticancer drugs are natural …

Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory

J Kashima, Y Okuma - Seminars in cancer biology, 2022 - Elsevier
Abstract Treatment for small cell lung cancer (SCLC) has not changed significantly
compared to the overwhelming development of targeted therapies for non-small cell lung …

Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage SCLC in the era of immunotherapy

M Torasawa, H Horinouchi, S Nomura, S Igawa… - Journal of Thoracic …, 2024 - Elsevier
Introduction Traditionally, relapsed SCLC has been classified as “sensitive” or “refractory” on
the basis of cutoff values (60 or 90 d) for the duration between the last chemotherapy and …

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: a systematic review and …

H Shi, N Guo, Z Zhao, L Liu, T Ni, J Zhang… - Frontiers in …, 2023 - frontiersin.org
Objective It remains unclear what the best second-line treatment is for patients with small-
cell lung cancer sensitive to previous platinum-based chemotherapy. Methods We …